Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma - Gabrielson, Andrew; Tesfaye, Anteneh A.; Marshall, John L.; Pishvaian, Michael J.; Smaglo, Brandon; Jha, Reena; Dorsch-Vogel, Karen; Wang, Hongkun; He, Aiwu Ruth (Cancer chemotherapy and pharmacology, 2015)
Keywords: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Benzimidazoles - administration & dosage; Benzimidazoles - adverse effects; Cancer Research; Carcinoma, Hepatocellular - drug therapy; Carcinoma, Hepatocellular - genetics; Dacarbazine - administration & dosage; Dacarbazine - adverse effects; Dacarbazine - analogs & derivatives; Dacarbazine - pharmacology; Disease-Free Survival; DNA Methylation - drug effects; DNA Repair - drug effects; DNA Repair - genetics; DNA, Neoplasm - genetics; DNA, Neoplasm - metabolism; Drug Resistance, Neoplasm; Fatigue - chemically induced; Female; Genes, BRCA1; Genes, BRCA2; Humans; Kaplan-Meier Estimate; Liver Neoplasms - drug therapy; Liver Neoplasms - genetics; Male; Medicine; Medicine & Public Health; Middle Aged; Niacinamide - analogs & derivatives; Niacinamide - pharmacology; Oncology; Original; Original Article; Pharmacology/Toxicology; Phenylurea Compounds - pharmacology; Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage; Poly(ADP-ribose) Polymerase Inhibitors - adverse effects; Salvage Therapy; Sorafenib; Temozolomide; Treatment Failure; Refractory; Hepatocellular carcinoma; Temozolomide; Veliparib